Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

Efficacy and Safety of Low-Dose Aztreonam in the Treatment of Moderate to Severe Infections Due to Gram-Negative Bacilli

Alain Clergeot, Dominique Steru, Marie-Anne Rosset and Claude Carbon
Reviews of Infectious Diseases
Vol. 13, Supplement 7. Aztreonam: The Expanding Clinical Profile (May - Jun., 1991), pp. S648-S651
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/4456016
Page Count: 4
  • Download ($42.00)
  • Subscribe ($19.50)
  • Cite this Item
Efficacy and Safety of Low-Dose Aztreonam in the Treatment of Moderate to Severe Infections Due to Gram-Negative Bacilli
Preview not available

Abstract

One hundred fifty-three patients with moderate to severe infections due to gram-negative bacilli, including septicemia (60 cases), lower respiratory tract infection (32 cases), intraabdominal infection (40 cases), and urinary tract infection (21 cases), were treated with aztreonam (1 g every 12 h). This dosage is lower than usual. Criteria for inclusion in the study included documented infection due to gram-negative bacilli and a measurement of severity of disease of <12 (as defined by a Simplified Acute Physiology Score for the 115 cases of community-acquired infection) or ≤1 (as defined by an Organ System Failure Score for 38 cases of nosocomial infection). Other than aztreonam, no antibiotic active against gram-negative bacilli was allowed to be used for treatment. Seventy-one patients in whom gram-positive or anaerobic organisms were detected or suspected were given additional agents effective against the organisms. One hundred forty-one patients (92.2%) were cured; the mean duration of treatment was 10.9 ± 4.0 days. None of the gram-negative bacilli initially isolated became resistant to aztreonam. Colonization, generally by a gram-positive organism, was observed in 27 patients and superinfection was observed in five. Aztreonam was well tolerated. This study suggests that a dosage of 2 g daily of aztreonam should be appropriate in the treatment of moderate to severe infections due to susceptible gram-negative bacilli.

Page Thumbnails

  • Thumbnail: Page 
S648
    S648
  • Thumbnail: Page 
S649
    S649
  • Thumbnail: Page 
S650
    S650
  • Thumbnail: Page 
S651
    S651